Evidence map›Paper›PMID 36435797›Full record

ArticleBiomaterials research2022

Modified exosomal SIRPα variants alleviate white matter injury after intracerebral hemorrhage via microglia/macrophages.

Xinjie Gao, Heng Yang, Weiping Xiao, Jiabin Su, Yuwen Zhang, He Wang, Wei Ni, Yuxiang Gu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. White Matter Injury in Central Nervous System Disorders.Neuropsychiatric disease and treatment · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Xinjie Gao *Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Heng Yang *Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Weiping XiaoDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Jiabin SuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Yuwen ZhangInstitute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, 200433, China.
He WangInstitute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, 200433, China. hewang@fudan.edu.cn.
Wei NiDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China. hsniwei@fudan.edu.cn.ORCID http://orcid.org/0000-0002-9550-3430
Yuxiang GuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China. guyuxiang1972@126.com.
Fudan University · CN

Funding

Ministry of Science and Technology of the People's Republic of China 2016YFC1301704National Natural Science Foundation of China 81771237National Natural Science Foundation of China 81870917National Natural Science Foundation of China 81971583
6 · The paper itself

Abstract

backgroundDespite limited efficiency, modulation of microglia/macrophages has shown to attenuate neuroinflammation after intracerebral hemorrhage (ICH). In this context, we evaluated the efficacy of modified exosomal signal regulatory protein α (SIRPα) variants (SIRPα-v Exos) in microglia/macrophages and neuroinflammation-associated white matter injury after ICH.

methodsSIRPα-v Exos were engineered to block CD47-SIRPα interactions. After obtaining SIRPα-v Exos from lentivirus-infected mesenchymal stem cells, C57BL/6 mice suffering from ICH underwent consecutive intravenous injections of SIRPα-v Exos (6 mg/kg) for 14 days. Afterwards, the volume of hematoma and neurological dysfunctions were assessed in mice continuously until 35 days after ICH. In addition, demyelination, electrophysiology and neuroinflammation were evaluated. Furthermore, the mechanisms of microglial regulation by SIRPα-v Exos were investigated in vitro under coculture conditions.

resultsThe results demonstrated that the clearance of hematoma in mice suffering from ICH was accelerated after SIRPα-v Exo treatment. SIRPα-v Exos improved long-term neurological dysfunction by ameliorating white matter injury. In addition, SIRPα-v Exos recruited regulatory T cells (Tregs) to promote M2 polarization of microglia/macrophages in the peri-hematoma tissue. In vitro experiments further showed that SIRPα-v Exos regulated primary microglia in a direct and indirect manner in synergy with Tregs.

conclusionOur studies revealed that SIRPα-v Exos could accelerate the clearance of hematoma and ameliorate secondary white matter injury after ICH through regulation of microglia/macrophages. SIRPα-v Exos may become a promising treatment for ICH in clinical practice.

Indexed as

ExosomeIntracerebral hemorrhageMicroglia/macrophagesSIRPα variantWhite matter injury

Identifiers

PMID36435797
PMCPMC9701394
OpenAlexW4310272400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.